NCT06876142 2026-04-17Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple MyelomaNational Institutes of Health Clinical Center (CC)Phase 1/2 Suspended54 enrolled